Cara Therapeutics Stock News

STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Tuesday, March 1, 2022, at 4:30 p.m. ET to report fourth quarter and full year 2021 financial results and provide a corporate update.

STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of

Cara Therapeutics, (NASDAQ:CARA) known for its research on cannabinoid receptor agonists for the relief of inflammatory and neuropathic pain, will host a virtual research and development event on F

Cara Therapeutics, (NASDAQ: CARA ) known for its research on cannabinoid receptor agonists for the relief of inflammatory and neuropathic pain, will host a virtual research and development event on Friday, March 11 from 1:00 to 2:00 … Full story available on Benzinga.com

Presentation to highlight oral difelikefalin Phase 3 pruritus programs Presentation to highlight oral difelikefalin Phase 3 pruritus programs

Joana Goncalves, MD, chief medical officer of Cara Therapeutics Brian Kim, MD, MTR,

Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Collegium (COLL) is set to acquire BioDelivery (BDSI) for approximately $604 million in cash. The transaction is likely to be completed by the end of first-quarter 2022.

Following a pre-BLA meeting with the FDA, Y-mAbs Therapeutics (YMAB) expects to resubmit its filing for omburtamabin CNS/leptomeningeal metastases from neuroblastoma by the end of first-quarter 2022.

The acquisitions of Vigene Biosciences and Cognate are likely to have a full-quarter favorable impact on Charles River's (CRL) Q4 Manufacturing Support revenues.

Illumina (ILMN) delivered earnings and revenue surprises of 50% and 0.75%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases fourth-quarter 2021 results.

On CRISPR Therapeutics' (CRSP) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates, especially its lead candidate CTX001.

Regeneron (REGN) delivered earnings and revenue surprises of 28.29% and 7.74%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

LabCorp's (LH) Covance Drug Development Q4 results are expected to reflect an increase in organic revenues on base business growth and contribution from COVID testing performed through the central lab